43 results about "Immunomodulin" patented technology

The invention relates to application of recombined ganoderma lucidum immnoregulation protein (rLZ-8) in preparation of medicine for treating melanin tumor. In-situ tumor and metastatic tumor experiment animal models are used to research anti-tumor effect of rLZ-8, and the results show that the rLZ-8 can evidently inhibit in-situ tumor growing and metastasis forming of the melanin tumor.

The invention provides a method for inhibiting EGF receptor activity comprising contacting an EGF receptor with an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof. Also provided is a method for treating invasion and metastasis of cancer cells, comprising administering an effective amount of an immunomodulatory protein (GMI) from Ganoderma microsporum, or a recombinant thereof, to a subject in need of such treatment.

The invention relates to the field of biological pharmacy and in particular relates to preparation and application of ganoderma lucidum immunoregulatory protein and fusion protein by a gene engineering technological means. A series of experiments show that an in-vivo half-life period prolonging effect of the fusion protein is more remarkable than that of rLZ-8, an improvement effect of the biological activity of the fusion protein is more remarkable than that of the rLZ-8, and in particular, and a leukocyte number increasing effect and an anti-tumor effect of the fusion protein are more remarkable than those of the rLZ-8 in the aspects of treating leucopenia and resisting tumor.

The invention discloses a recombinant ganoderma lucidum immunoregulatory protein mutant and application thereof. The invention finds that an anti-EGFR structural domain exists in an rLZ-8 protein structure, and particularly an EGFR abnormal expression tumor killing effect is induced through the positive potential characteristic of the structural region. On the basis of the scientific discovery, the rLZ-8 mutant protein with a stronger anti-tumor effect is obtained by a computer simulation technology.

The invention relates to a method for producing a trametes versicolor immunomodulatory protein by virtue of a pichia pastoris expression system. Problems about the preparation of trametes versicolor immunomodulatory proteins are effectively solved. The method comprises the following steps of synthesizing a nucleotide sequence SEQ ID NO.1 of a trametes versicolor immunomodulatory protein FIP-tvc according to a codon usage bias of pichia pastoris; constructing a recombinant expression plasmid X-FIP-tvc by virtue of the trametes versicolor immunomodulatory protein FIP-tvc synthesized by restriction enzyme digestion and an expression plasmid vector X, linearizing the recombinant expression plasmid X-FIP-tvc by virtue of a restriction enzyme, then transforming a competent cell of pichia pastoris GS115, screening a constitutive positive transformant or inducible positive transformant by virtue of an antibiotic-containing plate and PCR (Polymerase Chain Reaction) method, selecting an inducible high-level rFIP-tvc secretion expression pichia pastoris recombinant strain, performing fermental cultivation or induction expression for 3 to 7 days, precipitating fermentation supernatant with ammonium sulfate, performing dialysis on precipitates for 24 to 48 hours, performing affinity exchange chromatography with a chromatographic column, and performing drying to obtain solid powder of the trametes versicolor immunomodulatory protein FIP-tvc. The method is low in cost, short in cycle, easy to implement technically, suitable for industrial production and high in purity.

The invention relates to an application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma. According to the invention, the in-vivo anti-tumor effect of the rLZ-8 is researched by respectively building a lung cancer mice model by virtue of a caudal vein injection method and building a laryngocarcinoma and brain glioma nude mice animal model by virtue of a subcutaneous transplantation tumor method; a treatment result indicates that the rLZ-8 achieves an obvious anti-tumor effect on the lung cancer, the laryngocarcinoma and the brain glioma.

The invention provides a novel application of a recombinant ganoderma lucidum immunological regulation protein (rLZ-8) in treating thrombopenia. In the experiments of preventing and treating the thrombopenia of rats and dogs caused by cyclophosphamide, the rLZ-8 prepared from physiological saline carries out administration on an experimental animal model with lower thrombocytes, THPO and IL-6 areused as positive medicines, continuous administration is carried out, the number of the thrombocytes in blood is detected, the changes of the number of the thrombocytes before and after therapy are contrasted, and the medicine effect is analyzed. Compared with a model group, the rLZ-8 medicine group already obviously stimulates the thrombocyte proliferation of rats, Guinea pigs and dogs in the initial period (the 3rd day to the 5th day) of the administration, the difference is very obvious, the thrombocytes are recovered to a normal level in the middle period (the 7th day to the 10th day) of the administration, and the invention also obtains a very good effect in treating the thrombopenia of a Guinea pig experimental animal model caused by injecting anti-thrombocyte serum.

Disclosed is a ganoderma lucidum immunomodulatory protein mutant. The ganoderma lucidum immunomodulatory protein mutant comprises FIP-gluMN31S, FIP-gluMT36N and FIP-gluMN31S / T36N, wherein the amino acid sequence and the nucleotide sequence of the FIP-gluMN31S are shown as SEQ ID NO.1 and SEQ ID NO.4 respectively; the amino acid sequence and the nucleotide sequence of the FIP-gluMT36N are as shown in SEQ ID NO.2 and SEQ ID NO.5 respectively; and the amino acid sequence and the nucleotide sequence of the FIP-gluMN31S / T36N are shown as SEQ ID NO. 3 and SEQ ID NO. 6 respectively. According to the mutant, the problem that the toxicity of FIP-glu in application to cells is relatively high can be solved, the toxicity of the modified mutant to the cells is remarkably reduced compared with that of ganoderma lucidum immunomodulatory protein (FIP-glu), and the utilization value of the mutant can be effectively improved.

The present invention relates to a method for treating a refractory or relapsed lung cancer. Particularly, the invention provides a method and a formulation of using an immunomodulatory protein derived from Ganoderma microsporum in the treatment of a refractory or relapsed lung cancer.

The invention relates to Favolus arcularius Ames immunomodulatory protein Fip-Par1 and a preparation method and application thereof. The amino acid sequence of the immunomodulatory protein is defined as SEQ ID NO.1. The preparation method comprises the steps: (1) connecting the cDNA sequence of the Favolus arcularius Ames immunomodulatory protein into a carrier, and obtaining a recombinant vector; (2) converting the recombinant vector to a host cell, and obtaining a recombination strain; (3) cultivating the recombination strain, inducing and recombining the expression of the Favolus arcularius Ames immunomodulatory protein Fip-Par1; and (4), obtaining through the NI column purification and the dialysis segregation. The immunomodulatory protein is used for preparing health food. The Favolus arcularius Ames immunomodulatory protein Fip-Par1 obtained by recombination in vitro is capable of remarkably promoting the immunomodulatory effects, such as spleen lymphocyte proliferation and expression of tumor necrosis factor TNF-a, and has application potential for improving the body immunity.

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

The invention discloses a recombinant Ganoderma Lucidum immunomodulatory protein (rLZ-8) which has anti-tumor effect and is expressed by Pichia pastoris, and a pharmaceutical preparation thereof. The rLZ-8 has the effect of directly killing or damaging NB4 or K562 or HL-60 or S180 or H22 cells and not affecting normal cells; and the rLZ-8 can quickly and efficiently induce a plurality of tumor cells to apoptosize in vitro, can also effectively kill the tumor cells in a body of a mouse tumor model, has no obvious toxic side effect, and can keep or raise the level of leucocytes. In addition, the invention also provides an anti-tumor pharmaceutical preparation type taking the rLZ-8 as a core composition.

The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in reducing damage caused by fine particulate matter on embryos and offspring. Accordingly, the present invention suggests that the Ganoderma immunomodulatory protein administrated to pregnant animals can prevent neurological damages and reduce risk of disorders in embryos and offspring.

The invention relates to an application of a recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure. According to the invention, a rat cardiac failure model is established by intraperitoneal injection of adriamycin amycin (ADR) to study the curative effect of rLZ-8 to chronic cardiac failure. Experimental research results show that rLZ-8 can remarkably improve the cardiac function of the rat cardiac failure model, reduce the rate of myocardial apoptosis, reduce expression of relevant apoptin in myocardial cells (caspase3 and caspase9) and increase the survival rate of rats with chronic heart failure.

The present invention relates to a new use of an immunomodulatory protein derived from Ganoderma or a recombinant or a composition thereof in reducing damage caused by fine particulate matter on embryos and offspring. Accordingly, the present invention suggests that the Ganoderma immunomodulatory protein administrated to pregnant animals can prevent neurological damages and reduce risk of disorders in embryos and offspring.